NIKKEI 225
38,722.86 -200.17 (-0.51%) HANG SENG
18,403.04 +323.43 (+1.79%) CRUDE OIL
73.98 -0.24 (-0.32%) GOLD FUTURES
2,371.80 +2.50 (+0.11%) DOW
38,571.03 -115.29 (-0.30%) Bitcoin GBP
53,854.54 +955.01 (+1.81%)
GSK May 2024 45.000 call
| Previous close | 0.1300 |
| Open | 0.0900 |
| Bid | 0.0000 |
| Ask | 0.1500 |
| Strike | 45.00 |
| Expiry date | 2024-05-31 |
| Day's range | 0.0300 - 0.0900 |
| Contract range | N/A |
| Volume | |
| Open interest | 523 |
- Yahoo Finance Video
GSK stock sinks after court allows Zantac lawsuits to proceed
Shares of Britain-based pharmaceutical company GSK plc (GSK) — formerly known as GlaxoSmithKline — are sliding in pre-market trading and into Monday's session open following a court ruling that has approved more than 70,000 lawsuits to go forward over heartburn medication Zantac's alleged links to cancer. For more expert insight and the latest market action, click here to watch this full episode of Morning Brief. This post was written by Luke Carberry Mogan.
BenzingaGSK's Blenrep Combo Therapy Cuts Risk Of Disease Progression Or Death By Around 50% In Pretreated Multiple Myeloma
On Sunday, GSK plc (NYSE:GSK) released results from an interim analysis of the DREAMM-8 phase 3 head-to-head trial evaluating Blenrep (belantamab mafodotin) in combination with pomalidomide plus dexamethasone (PomDex), versus a standard of care, bortezomib plus PomDex for relapsed or refractory multiple myeloma. The data were presented at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting. On the primary endpoint of progression-free survival (PFS), the belantamab mafodotin comb
The TelegraphOil price slumps by 4pc despite Opec cuts
Oil prices have slumped nearly 4pc despite Opec production cuts amid signs that Saudi Arabia will struggle to maintain caps on future supply.
